Avi Tsafrir
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Avi Tsafrir has a total of 92 co-authors. Here are the top co-authors by number of shared publications:
Jordana Hyman
Faculty of Medicine, Hebrew University of Jerusalem. IVF Unit, Department of Obstetrics and Gynecology, Shaare Zedek Medical Center, Jerusalem, Israel
4 shared publicationsTalia Eldar-Geva
IVF Unit, Department of Obstetrics and Gynecology, Shaare Zedek Medical Center, Jerusalem, Israel
4 shared publicationsAriel Weissman
Faculty of Medical & Health Sciences, Tel Aviv University, Tel Aviv, Israel. IVF Unit, Department of Obstetrics and Gynecology, Edith Wolfson Medical Center, Holon, Israel
3 shared publicationsDoron Goldberg
Clalit Health Services, Fertility clinic, Modi’in Illit, Israel
3 shared publications- Ido Ben-Ami
Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel
3 shared publications Michael Gal
IVF Unit, Department of Obstetrics and Gynecology, Shaare Zedek Medical Center, Jerusalem, Israel
3 shared publications
Latest Publications
- 23 September 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (13) , 10998-10999
ASO Visual Abstract: Fertility Preservation Pathways for Young Women with Breast Cancer: A Single-Center Analysis in a Publicly Funded System
- 23 September 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (13) , 10998-10999
ASO Visual Abstract: Fertility Preservation Pathways for Young Women with Breast Cancer: A Single-Center Analysis in a Publicly Funded System
- Open Access
- 26 August 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (13) , 10909-10917
Fertility Preservation Pathways in Young Women With Breast Cancer: A Single-Center Analysis in a Publicly Funded System
Background: Fertility concerns are central to the care of young women with breast cancer. Cancer treatments and chemotherapeutic regimens may adversely affect reproductive potential. Despite extensive attention to fertility preservation (FP), reported uptake remains low. It remains unclear how patients progress through the fertility preservation process within publicly funded health care systems that reduce financial and access barriers. Methods: Key time points in the patient care sequence were assessed, beginning with the initial oncology or surgical consultation, at which fertility discussion (FD), defined as counseling by an oncologist or breast surgeon, could occur, followed by fertility consultation (FC), defined as consultation with a fertility specialist, and uptake of FP, including oocyte, embryo, or ovarian tissue cryopreservation, but not hormonal ovarian protection. Results: Among 248 women, 77.8% had FD, 40.7% underwent FC, and 27.4% proceeded to FP. The largest reduction occurred between the FD and the FC, whereas progression from consultation to preservation remained high. Although women aged 40 years or older and those with two or more children were less likely to proceed to FC and FP, they still represented a measurable proportion of those undergoing preservation. Conclusion: Fertility discussions were documented for most patients, and progression from FC to FP was high. The overall proportion of women undergoing FP was higher than previously reported in earlier studies. These findings suggest that previously reported low utilization rates may not fully capture patients' interest in FP and may, in part, be attributable to differences in patterns of care delivery.
- 26 August 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (13) , 10909-10917
Open AccessFertility Preservation Pathways in Young Women With Breast Cancer: A Single-Center Analysis in a Publicly Funded System
Background: Fertility concerns are central to the care of young women with breast cancer. Cancer treatments and chemotherapeutic regimens may adversely affect reproductive potential. Despite extensive attention to fertility preservation (FP), reported uptake remains low. It remains unclear how patients progress through the fertility preservation process within publicly funded health care systems that reduce financial and access barriers. Methods: Key time points in the patient care sequence were assessed, beginning with the initial oncology or surgical consultation, at which fertility discussion (FD), defined as counseling by an oncologist or breast surgeon, could occur, followed by fertility consultation (FC), defined as consultation with a fertility specialist, and uptake of FP, including oocyte, embryo, or ovarian tissue cryopreservation, but not hormonal ovarian protection. Results: Among 248 women, 77.8% had FD, 40.7% underwent FC, and 27.4% proceeded to FP. The largest reduction occurred between the FD and the FC, whereas progression from consultation to preservation remained high. Although women aged 40 years or older and those with two or more children were less likely to proceed to FC and FP, they still represented a measurable proportion of those undergoing preservation. Conclusion: Fertility discussions were documented for most patients, and progression from FC to FP was high. The overall proportion of women undergoing FP was higher than previously reported in earlier studies. These findings suggest that previously reported low utilization rates may not fully capture patients' interest in FP and may, in part, be attributable to differences in patterns of care delivery.
- Open Access
- 7 August 2026
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 43 (9) , 2963-2970
Alignment between expanded carrier screening panels and conditions leading to PGT-M: a real-world cohort study
Purpose: To assess the extent to which expanded carrier screening (ECS) panels capture the genetic conditions for which preimplantation genetic testing for monogenic diseases (PGT-M) is performed. Methods: A retrospective observational study conducted at a single university-affiliated PGT unit from 2015 to 2023. Women undergoing PGT-M for autosomal recessive or X-linked genetic conditions were included. Genetic conditions were cross-matched with five ECS panels (four commercial panels and one publicly funded ECS panel) and compared with a targeted, population-specific screening. Coverage was assessed at both the woman and gene levels using paired statistical comparisons. Results: A total of 330 cases were included; seven women underwent PGT-M for two eligible conditions and were therefore counted twice. These cases involved 110 different genes with an uneven distribution: eight genes accounted for 53.2% of cases, while 71 genes were observed in a single case. At the individual-woman level, targeted, population-specific screening showed lower coverage (47.9%) than that of all ECS panels (71.8–91.5%), with overall differences statistically significant ( P < 0.001). At the gene level, coverage ranged from 20.9 to 79.1% across panels ( P < 0.001). The evaluated ECS panels included 271–787 genes, with the largest panel demonstrating higher case coverage than the other commercial panels. Conclusions: Expanded carrier screening panels capture most autosomal recessive and X-linked genetic conditions for which PGT-M is performed. These findings support the clinical utility of ECS in identifying couples at risk of having children affected by such conditions.
- 7 August 2026
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 43 (9) , 2963-2970
Open AccessAlignment between expanded carrier screening panels and conditions leading to PGT-M: a real-world cohort study
Purpose: To assess the extent to which expanded carrier screening (ECS) panels capture the genetic conditions for which preimplantation genetic testing for monogenic diseases (PGT-M) is performed. Methods: A retrospective observational study conducted at a single university-affiliated PGT unit from 2015 to 2023. Women undergoing PGT-M for autosomal recessive or X-linked genetic conditions were included. Genetic conditions were cross-matched with five ECS panels (four commercial panels and one publicly funded ECS panel) and compared with a targeted, population-specific screening. Coverage was assessed at both the woman and gene levels using paired statistical comparisons. Results: A total of 330 cases were included; seven women underwent PGT-M for two eligible conditions and were therefore counted twice. These cases involved 110 different genes with an uneven distribution: eight genes accounted for 53.2% of cases, while 71 genes were observed in a single case. At the individual-woman level, targeted, population-specific screening showed lower coverage (47.9%) than that of all ECS panels (71.8–91.5%), with overall differences statistically significant ( P < 0.001). At the gene level, coverage ranged from 20.9 to 79.1% across panels ( P < 0.001). The evaluated ECS panels included 271–787 genes, with the largest panel demonstrating higher case coverage than the other commercial panels. Conclusions: Expanded carrier screening panels capture most autosomal recessive and X-linked genetic conditions for which PGT-M is performed. These findings support the clinical utility of ECS in identifying couples at risk of having children affected by such conditions.
- Open Access
- 2 June 2025
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 42 (7) , 2305-2311
Managing parental capacity concerns in IVF: the role of child welfare committees—a survey of unit directors
Purpose: To examine whether Child Welfare Advisory Committees (CWCs) assist IVF unit directors in addressing concerns about prospective parental capacity (PC). Methods: An anonymous online survey of 26 IVF unit directors in Israel was conducted in November 2023, focusing on referrals to CWCs, reasons for referral, and satisfaction with CWC services. Results: Of the 26 directors, 23 responded (88%). Over a 3-year period, 21 (91%) reported referring candidates to CWCs, with referral counts ranging from 1 to “over 30.” The most frequently cited concerns were cognitive developmental disability (16 directors, 72%), mental illness (also 16, 72%), and severe physical disability (10, 43%). Thirteen directors (57%) rated CWC availability and quality as reasonable, while five (21%) found services insufficient, and three (13%) reported no access at all. Ten directors (43%) used alternative strategies, including denying treatment without CWC input, referring patients elsewhere, or prolonging the assessment to encourage withdrawal. One in four respondents reported facing legal or administrative challenges following further evaluation requests or treatment refusals. Conclusions: Concerns about prospective PC are relatively uncommon but present in all IVF units. The most frequent concerns relate to cognitive developmental disability, mental illness, and severe physical disabilities. While most directors consult CWCs in such cases, satisfaction with their function is mixed. These findings highlight the need for clearer guidelines and more accessible, consistent consultation structures to support clinicians in managing complex cases.
- 2 June 2025
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 42 (7) , 2305-2311
Open AccessManaging parental capacity concerns in IVF: the role of child welfare committees—a survey of unit directors
Purpose: To examine whether Child Welfare Advisory Committees (CWCs) assist IVF unit directors in addressing concerns about prospective parental capacity (PC). Methods: An anonymous online survey of 26 IVF unit directors in Israel was conducted in November 2023, focusing on referrals to CWCs, reasons for referral, and satisfaction with CWC services. Results: Of the 26 directors, 23 responded (88%). Over a 3-year period, 21 (91%) reported referring candidates to CWCs, with referral counts ranging from 1 to “over 30.” The most frequently cited concerns were cognitive developmental disability (16 directors, 72%), mental illness (also 16, 72%), and severe physical disability (10, 43%). Thirteen directors (57%) rated CWC availability and quality as reasonable, while five (21%) found services insufficient, and three (13%) reported no access at all. Ten directors (43%) used alternative strategies, including denying treatment without CWC input, referring patients elsewhere, or prolonging the assessment to encourage withdrawal. One in four respondents reported facing legal or administrative challenges following further evaluation requests or treatment refusals. Conclusions: Concerns about prospective PC are relatively uncommon but present in all IVF units. The most frequent concerns relate to cognitive developmental disability, mental illness, and severe physical disabilities. While most directors consult CWCs in such cases, satisfaction with their function is mixed. These findings highlight the need for clearer guidelines and more accessible, consistent consultation structures to support clinicians in managing complex cases.
- Open Access
- 1 January 2025
- Published by GN1 Sistemas e Publicacoes Ltd. in JBRA Assisted Reproduction
- Vol. 29 (3) , 467-472
The Approach of Fertility Physicians to Donor Sperm Treatments: A Worldwide Survey
Many women presenting for treatment with donor sperm have never attempted conception, and are therefore presumed fertile. With no clear guidelines, treatment can be influenced by factors like patient age and costs. We aimed to explore fertility physicians' attitudes and clinical practices regarding donor sperm treatments through a global survey. We conducted an anonymous international web-based survey of fertility clinicians. The survey addressed various aspects of donor sperm treatment in women without previous infertility. A total of 211 clinicians participated, with 63% working in private settings. The survey presented clinical scenarios for women aged 32, 37, and 40. Most clinicians (80%) recommended artificial insemination with donor sperm in a natural cycle (NC-AID) as the first-line treatment for a 32-year-old woman (52% suggested up to 3 cycles, 28% up to 6 cycles). This approach was favored by 45% for a 37-year-old and 25% for a 40-year-old. Variability was noted regarding the second-line treatment for a 32-year-old after one failed NC-AID varied (equal recommendations for ovarian stimulation with oral agents, gonadotropins, or IVF). For older women, active management was preferred: 24% recommended gonadotropins and 15% IVF for 37-year-olds, and 16% gonadotropins and 55% IVF for 40-year-olds. This survey highlights the controversy surrounding the optimal approach for women with no history of infertility seeking to conceive with donor sperm. Our findings emphasize the need for further research and the development of comprehensive guidelines in this area.
- 1 January 2025
- Published by GN1 Sistemas e Publicacoes Ltd. in JBRA Assisted Reproduction
- Vol. 29 (3) , 467-472
Open AccessThe Approach of Fertility Physicians to Donor Sperm Treatments: A Worldwide Survey
Many women presenting for treatment with donor sperm have never attempted conception, and are therefore presumed fertile. With no clear guidelines, treatment can be influenced by factors like patient age and costs. We aimed to explore fertility physicians' attitudes and clinical practices regarding donor sperm treatments through a global survey. We conducted an anonymous international web-based survey of fertility clinicians. The survey addressed various aspects of donor sperm treatment in women without previous infertility. A total of 211 clinicians participated, with 63% working in private settings. The survey presented clinical scenarios for women aged 32, 37, and 40. Most clinicians (80%) recommended artificial insemination with donor sperm in a natural cycle (NC-AID) as the first-line treatment for a 32-year-old woman (52% suggested up to 3 cycles, 28% up to 6 cycles). This approach was favored by 45% for a 37-year-old and 25% for a 40-year-old. Variability was noted regarding the second-line treatment for a 32-year-old after one failed NC-AID varied (equal recommendations for ovarian stimulation with oral agents, gonadotropins, or IVF). For older women, active management was preferred: 24% recommended gonadotropins and 15% IVF for 37-year-olds, and 16% gonadotropins and 55% IVF for 40-year-olds. This survey highlights the controversy surrounding the optimal approach for women with no history of infertility seeking to conceive with donor sperm. Our findings emphasize the need for further research and the development of comprehensive guidelines in this area.
- Open Access
- 5 September 2024
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 41 (11) , 2973-2977
Trends in patient age at planned oocyte cryopreservation
Purpose: The outcome of planned oocyte cryopreservation (POC) is inversely related to the age at the time of oocyte cryopreservation commencing in the mid-30 s. We sought to evaluate whether the age of women undergoing POC has changed over the last decade. Methods: The study employed a retrospective, observational multicenter design. It included all women who had at least one POC cycle in two large private IVF units belonging to the same medical organization in Israel. The main outcome measure was age at the first cycle. Data on the total number of women each year and their age at the first cycle were recorded. Results: Between 2011 and the end of 2023, 4488 women underwent POC. The average age at the first retrieval was 36.2 years (± 2.4). In 2011, the average age was 38.3 years (± 2.6), which decreased to 35.4 years (± 2.5) in 2023. The trendline indicates a decline in the average age of 3.0 months per year (β = − 0.252, F = 301.8, p < 0.001). The proportion of women aged < 36 at their first POC cycle increased from 14% in 2011 to 54% in 2023. Conclusions: The age at the time of POC has significantly declined over the past decade. This trend may potentially lead to higher overall birth rates from POC, though further research is needed to confirm this hypothesis.
- 5 September 2024
- Published by Springer Nature in Journal of Assisted Reproduction and Genetics
- Vol. 41 (11) , 2973-2977
Open AccessTrends in patient age at planned oocyte cryopreservation
Purpose: The outcome of planned oocyte cryopreservation (POC) is inversely related to the age at the time of oocyte cryopreservation commencing in the mid-30 s. We sought to evaluate whether the age of women undergoing POC has changed over the last decade. Methods: The study employed a retrospective, observational multicenter design. It included all women who had at least one POC cycle in two large private IVF units belonging to the same medical organization in Israel. The main outcome measure was age at the first cycle. Data on the total number of women each year and their age at the first cycle were recorded. Results: Between 2011 and the end of 2023, 4488 women underwent POC. The average age at the first retrieval was 36.2 years (± 2.4). In 2011, the average age was 38.3 years (± 2.6), which decreased to 35.4 years (± 2.5) in 2023. The trendline indicates a decline in the average age of 3.0 months per year (β = − 0.252, F = 301.8, p < 0.001). The proportion of women aged < 36 at their first POC cycle increased from 14% in 2011 to 54% in 2023. Conclusions: The age at the time of POC has significantly declined over the past decade. This trend may potentially lead to higher overall birth rates from POC, though further research is needed to confirm this hypothesis.
- 10 June 2024
- Published by Oxford University Press (OUP) in Human Reproduction Update
- Vol. 30 (5) , 650
Reply: What is the expected live birth rate per thawed oocyte?
- 10 June 2024
- Published by Oxford University Press (OUP) in Human Reproduction Update
- Vol. 30 (5) , 650
Reply: What is the expected live birth rate per thawed oocyte?
- Top Cited Papers
- 24 April 2024
- Published by Oxford University Press (OUP) in Human Reproduction Update
- Vol. 30 (5) , 558-568
Planned oocyte cryopreservation: a systematic review and meta-regression analysis
Awareness of the age-related decline in fertility potential has increased the popularity of planned oocyte cryopreservation (POC). However, data regarding outcomes of POC, including rates of women returning to thaw oocytes, as well as pregnancy and live birth rates, are scarce and based mostly on small case series. POC was defined as cryopreservation exclusively for prevention of future age-related fertility loss. The primary outcome was live birth rate per patient. The secondary outcomes included the return to thaw rate and laboratory outcomes. A meta-regression analysis examining the association between live birth and age above 40 or below 35 was conducted. We conducted a systematic database search from inception to August 2022. The search included PubMed (MEDLINE) and EMBASE. Our search strategies employed a combination of index terms (Mesh) and free text words to compile relevant concepts. The systematic review and meta-regression were undertaken following registration of systematic review (PROSPERO registration number CRD42022361791) and were reported following guidelines of Preferred Reporting Items for Systematic Review and Meta-Analyses 2020 (PRISMA 2020). The database search yielded 3847 records. After the selection process, 10 studies, conducted from 1999 to 2020, were included. Overall, 8750 women underwent POC, with a mean cryopreservation age of 37.2 (±0.8). Of those, 1517 women returned to use their oocytes with a return rate of 11.1% (± 4.7%). The mean age at the time of cryopreservation for women who returned to use their oocytes was 38.1 (±0.4), with an average of 12.6 (±3.6) cryopreserved oocytes per woman. In a meta-analysis, the oocyte survival rate was 78.5% with a 95% CI of 0.74–0.83 (I2 = 93%). The live birth rate per patient was 28% with a 95% CI of 0.24–0.33 (I2 = 92%). Overall, 447 live births were reported. In a sub-group analysis, women who underwent cryopreservation at age ≥40 achieved a live birth rate per patient of 19% (95% CI 0.13–0.29, I2 = 6%), while women aged ≤35 years old or younger had a higher live birth rate per patient of 52% (95% CI 0.41–0.63, I2 = 7%). POC emerges as a feasible option for women aiming to improve their chances of conceiving at a later reproductive age. Nonetheless, it must be acknowledged that the overall success rates of POC are limited and that the likelihood of successful live birth declines as the age at cryopreservation rises. With increasing interest in POC, the collation of comprehensive and high-quality data is imperative to clearly define the outcomes for various age groups. CRD42022361791. In meta-analysis, Planned Oocyte Cryopreservation yielded 28% live birth rate, strongly correlated with age at cryopreservation.
- 24 April 2024
- Published by Oxford University Press (OUP) in Human Reproduction Update
- Vol. 30 (5) , 558-568
Top Cited PapersPlanned oocyte cryopreservation: a systematic review and meta-regression analysis
Awareness of the age-related decline in fertility potential has increased the popularity of planned oocyte cryopreservation (POC). However, data regarding outcomes of POC, including rates of women returning to thaw oocytes, as well as pregnancy and live birth rates, are scarce and based mostly on small case series. POC was defined as cryopreservation exclusively for prevention of future age-related fertility loss. The primary outcome was live birth rate per patient. The secondary outcomes included the return to thaw rate and laboratory outcomes. A meta-regression analysis examining the association between live birth and age above 40 or below 35 was conducted. We conducted a systematic database search from inception to August 2022. The search included PubMed (MEDLINE) and EMBASE. Our search strategies employed a combination of index terms (Mesh) and free text words to compile relevant concepts. The systematic review and meta-regression were undertaken following registration of systematic review (PROSPERO registration number CRD42022361791) and were reported following guidelines of Preferred Reporting Items for Systematic Review and Meta-Analyses 2020 (PRISMA 2020). The database search yielded 3847 records. After the selection process, 10 studies, conducted from 1999 to 2020, were included. Overall, 8750 women underwent POC, with a mean cryopreservation age of 37.2 (±0.8). Of those, 1517 women returned to use their oocytes with a return rate of 11.1% (± 4.7%). The mean age at the time of cryopreservation for women who returned to use their oocytes was 38.1 (±0.4), with an average of 12.6 (±3.6) cryopreserved oocytes per woman. In a meta-analysis, the oocyte survival rate was 78.5% with a 95% CI of 0.74–0.83 (I2 = 93%). The live birth rate per patient was 28% with a 95% CI of 0.24–0.33 (I2 = 92%). Overall, 447 live births were reported. In a sub-group analysis, women who underwent cryopreservation at age ≥40 achieved a live birth rate per patient of 19% (95% CI 0.13–0.29, I2 = 6%), while women aged ≤35 years old or younger had a higher live birth rate per patient of 52% (95% CI 0.41–0.63, I2 = 7%). POC emerges as a feasible option for women aiming to improve their chances of conceiving at a later reproductive age. Nonetheless, it must be acknowledged that the overall success rates of POC are limited and that the likelihood of successful live birth declines as the age at cryopreservation rises. With increasing interest in POC, the collation of comprehensive and high-quality data is imperative to clearly define the outcomes for various age groups. CRD42022361791. In meta-analysis, Planned Oocyte Cryopreservation yielded 28% live birth rate, strongly correlated with age at cryopreservation.
- Open Access
- 24 August 2023
- Published by Springer Nature in Reproductive Biology and Endocrinology
- Vol. 21 (1) , 1-7
What are the most common controversial clinical issues in fertility preservation? A content analysis of a collaborative professional online consultation group
Research question: Clinicians involved in fertility preservation (FP) are often required to make prompt and consequential decisions despite the absence of evidence-based data. We established a collaborative professional online consultation group for fertility preservation issues. We sought to determine the main controversial clinical issues in FP as raised by participants of this group. Design: Content analysis of a dedicated community of practice interacting via a messaging application (WhatsApp) and a survey of group participants. Results: Between January 2019 and July 2022, group members posed 39 clinical questions which were discussed and debated by the group. Common themes included management of oncofertility cases (33%), potential gonadotoxicity of various therapies (23%), fertility preservation in women and girls with premature ovarian insufficiency (POI) (18%), and technical aspects of ovarian tissue cryopreservation (10%). All but one query received prompt response (mean time for first response for 95% of queries 7.1 ± 9.0 min) from a mean of 5.4 ± 3.2 members. An anonymous online survey of group members was conducted during August 2022 (n = 31, response rate 94%). The majority of respondents stated they gained knowledge and assistance in clinical decision making from participation in the discussion group (90% and 58% of respondents, respectively). Conclusions: Management of clinical oncofertility cases, potential gonadotoxic effect of therapeutics and fertility preservation in women and girls with POI were the most common controversial issues in our fertility preservation community of practice. Intra-professional collaborative communication via a messaging application can aid in clinical management of fertility preservation and augment clinician’s knowledge.
- 24 August 2023
- Published by Springer Nature in Reproductive Biology and Endocrinology
- Vol. 21 (1) , 1-7
Open AccessWhat are the most common controversial clinical issues in fertility preservation? A content analysis of a collaborative professional online consultation group
Research question: Clinicians involved in fertility preservation (FP) are often required to make prompt and consequential decisions despite the absence of evidence-based data. We established a collaborative professional online consultation group for fertility preservation issues. We sought to determine the main controversial clinical issues in FP as raised by participants of this group. Design: Content analysis of a dedicated community of practice interacting via a messaging application (WhatsApp) and a survey of group participants. Results: Between January 2019 and July 2022, group members posed 39 clinical questions which were discussed and debated by the group. Common themes included management of oncofertility cases (33%), potential gonadotoxicity of various therapies (23%), fertility preservation in women and girls with premature ovarian insufficiency (POI) (18%), and technical aspects of ovarian tissue cryopreservation (10%). All but one query received prompt response (mean time for first response for 95% of queries 7.1 ± 9.0 min) from a mean of 5.4 ± 3.2 members. An anonymous online survey of group members was conducted during August 2022 (n = 31, response rate 94%). The majority of respondents stated they gained knowledge and assistance in clinical decision making from participation in the discussion group (90% and 58% of respondents, respectively). Conclusions: Management of clinical oncofertility cases, potential gonadotoxic effect of therapeutics and fertility preservation in women and girls with POI were the most common controversial issues in our fertility preservation community of practice. Intra-professional collaborative communication via a messaging application can aid in clinical management of fertility preservation and augment clinician’s knowledge.
- Open Access
- 28 June 2023
- Published by Springer Nature in Research Square
What are the most common controversial clinical issues in fertility preservation? A content analysis of a collaborative professional online consultation group
Research Question Clinicians involved in fertility preservation (FP) are often required to make prompt and consequential decisions despite the absence of evidence-based data. We established a collaborative professional online consultation group for fertility preservation issues. We sought to determine the main controversial clinical issues in FP as raised by participants of this group. Design Content analysis of a dedicated community of practice interacting via a messaging application (WhatsApp) and a survey of group participants. Results Between January 2019 and July 2022, group members posed 39 clinical questions which were discussed and debated by the group. Common themes included management of oncofertility cases (33%), potential gonadotoxicity of various therapies (23 %), fertility preservation in women and girls with premature ovarian insufficiency (POI) (18%), and technical aspects of ovarian tissue cryopreservation (10%). All but one query received prompt response (mean time for first response for 95% of queries 7.1±9.0 minutes) from a mean of 5.4±3.2 members. An anonymous online survey of group members was conducted during August 2022 (n=31, response rate 94%). The majority of respondents stated they gained knowledge and assistance in clinical decision making from participation in the discussion group (90% and 58% of respondents, respectively). Conclusions Management of clinical oncofertility cases, potential gonadotoxic effect of therapeutics and fertility preservation in women and girls with POI were the most common controversial issues in our fertility preservation community of practice. Intra-professional collaborative communication via a messaging application can aid in clinical management of fertility preservation and augment clinician’s knowledge.
- 28 June 2023
- Published by Springer Nature in Research Square
Open AccessWhat are the most common controversial clinical issues in fertility preservation? A content analysis of a collaborative professional online consultation group
Research Question Clinicians involved in fertility preservation (FP) are often required to make prompt and consequential decisions despite the absence of evidence-based data. We established a collaborative professional online consultation group for fertility preservation issues. We sought to determine the main controversial clinical issues in FP as raised by participants of this group. Design Content analysis of a dedicated community of practice interacting via a messaging application (WhatsApp) and a survey of group participants. Results Between January 2019 and July 2022, group members posed 39 clinical questions which were discussed and debated by the group. Common themes included management of oncofertility cases (33%), potential gonadotoxicity of various therapies (23 %), fertility preservation in women and girls with premature ovarian insufficiency (POI) (18%), and technical aspects of ovarian tissue cryopreservation (10%). All but one query received prompt response (mean time for first response for 95% of queries 7.1±9.0 minutes) from a mean of 5.4±3.2 members. An anonymous online survey of group members was conducted during August 2022 (n=31, response rate 94%). The majority of respondents stated they gained knowledge and assistance in clinical decision making from participation in the discussion group (90% and 58% of respondents, respectively). Conclusions Management of clinical oncofertility cases, potential gonadotoxic effect of therapeutics and fertility preservation in women and girls with POI were the most common controversial issues in our fertility preservation community of practice. Intra-professional collaborative communication via a messaging application can aid in clinical management of fertility preservation and augment clinician’s knowledge.